J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer

被引：6
|
作者：
Gainor, Justin F. [1 ]
Shaw, Alice T. [1 ]
机构：
[1] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
来源：
LANCET | 2017年 / 390卷 / 10089期
关键词：
PROGRESSION-FREE; OPEN-LABEL; CHEMOTHERAPY; CERITINIB; SURVIVAL;
D O I：
10.1016/S0140-6736(17)31074-7
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3 / 4
页数：2
相关论文
共 50 条
  • [31] FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib
    Larkins, Erin
    Blumenthal, Gideon M.
    Chen, Huanyu
    He, Kun
    Agarwal, Rajiv
    Gieser, Gerlie
    Stephens, Olen
    Zahalka, Eias
    Ringgold, Kimberly
    Helms, Whitney
    Shord, Stacy
    Yu, Jingyu
    Zhao, Hong
    Davis, Gina
    McKee, Amye E.
    Keegan, Patricia
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2016, 22 (21) : 5171 - 5176
  • [32] Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
    Peter N. Morcos
    Eveline Nueesch
    Felix Jaminion
    Elena Guerini
    Joy C. Hsu
    Walter Bordogna
    Bogdana Balas
    Francois Mercier
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 129 - 138
  • [33] The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer
    Pender, Alexandra
    Popat, Sanjay
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (03) : 97 - 104
  • [34] Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer
    Ji, Cheng
    Zhang, Li
    Cheng, Yan
    Patel, Raj
    Wu, Hao
    Zhang, Yi
    Wang, Mian
    Ji, Shundong
    Belani, Chandra P.
    Yang, Jin-Ming
    Ren, Xingcong
    CANCER BIOLOGY & THERAPY, 2014, 15 (05) : 570 - 577
  • [35] Expanding opportunities for crizotinib resistance in ALK-positive lung cancer patients
    Ilie, Marius
    Hofman, Paul
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 (02) : 203 - 205
  • [36] Advanced ALK-positive lung cancer with lorlatinib versus crizotinib in Asian patients with brain metastases
    Shih-Chang, Hung
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2023, 30 (01)
  • [37] First-Line Crizotinib in ALK-Positive Lung Cancer REPLY
    Solomon, Benjamin J.
    Mok, Tony
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 782 - 782
  • [38] Complete response to alectinib following crizotinib in an ALK-positive tumor with CNS involvement
    Xavier, Camila B.
    Canedo, Felipe S. N. A.
    Lima, Fabiola A. S.
    Melo, Raissa R.
    Lima, Luiz Guilherme C. A.
    Marin, Jose Flavio G.
    Souza, Ciro E.
    Feher, Olavo
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2021, 4
  • [39] Impact of alectinib on survival after crizotinib failure in ALK-positive NSCLC patients
    Yoshida, T.
    Oya, Y.
    Tanaka, K.
    Junichi, S.
    Yoshitsugu, H.
    Hida, T.
    Yatabe, Y.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S619 - S619
  • [40] Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer
    Koizumi, Tomonobu
    Fukushima, Toshirou
    Tatai, Toshiharu
    Kobayashi, Takashi
    Sekiguchi, Nodoka
    Sakamoto, Akiyuki
    Sasaki, Shigeru
    LUNG CANCER, 2015, 88 (01) : 112 - 113
12345